Long-term topotecan therapy in recurrent or persistent ovarian cancer

European Journal of Gynaecological Oncology

Volumn 32, Issue 2, 2011, Pages 153-155

  Cormio, G ^a   Loizzi, V ^a   Gissi, F ^a   Camporeale, A ^a   De Mitri, P ^a   Leone, L ^a   Putignano, G ^a   Selvaggi, L ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Ovarian carcinoma; Recurrent ovarian cancer; Topotecan

Indexed keywords

DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; INFORMATION PROCESSING; ITALY; LEUKOPENIA; LONG TERM CARE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHLEBITIS; RECURRENT CANCER; RECURRENT OVARIAN CARCINOMA; RECURRENT OVARY CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 79955693446     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wing P.A., Tong T., Bolden S.: "Cancer statistics". CA Cancer J. Clin., 1995, 45, 8.
2. Harries M., Gore M.: "Chemotherapy for epithelial ovarian cancer. Treatment of recurrent disease". Lancet Oncol., 2002, 3, 537.
3. Markman M., Bookman M.A.: "Second-line treatment of ovarian cancer". Oncologist, 2000, 5, 26.
4. Mobus V., Kieback D.G., Kaubitzsch S.K.: "Duration of chemotherapy with topotecan influences survival in recurent ovarian cancer: a meta-analysis". Anticancer Res., 2007, 27, 1581.
5. International Federation of Gynecology and Obstetrics: "Changes in definitions of clinical staging for carcinoma of the cervix and ovary". Am. J. Obstet. Gynecol., 1987, 156, 263.
6. Therasse P., Arbuck Sg., Eisenhauer E.A. et al.: "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada". J. Natl. Cancer Inst., 2000, 92, 205.
7. Ozols R.F.: "Maintenance therapy in advanced ovarian cancer:progression-free survival and clinical benefit". J. Clin. Oncol., 2003, 21, 2451.
8. Markman M., Liu P.Y., Wilczynski S. et al.: "Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with dvanced ovarian cancer after complete response to platiunum and paclitaxel based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial". J. Clin. Oncol., 203, 21, 2460.
9. Spriggs D.: "Duration of therapy for ovarian cancer: how long is enough?. Cancer Invest., 2004, 1 (suppl.), 44.
10. Markman M., Markman J., Webster K. et al.: "Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implication for patient management and clinical trial design". J. Clin. Oncol., 2004, 22, 3120.
11. Spriggs D.: "Optimal sequencing in the treatment of recurrent ovarian cancer". Gynecol. Oncol., 2003, 90 (3 suppl. 1), S39.
12. Andreopolou E., Gaiotti D., Kim E. et al.: "Pegylated liposomal doxorubicin HCL (PLD; Caelys/Doxil): experience with long-term maintenance in responding patiens with recurrent epithelial ovarian cancer". Ann. Oncol., 2007, 18, 716.